GNTA vs IKT

Genenta Science S.p.A. vs Inhibikase Therapeutics, Inc. — Valuation Comparison 2026

GNTA

Biological Products, (No Diagnostic Substances)
Genenta Science S.p.A.
Quality
4.7
out of 10
Value Trap
12
SAFE
Price
$1.03
Last close
Models
7/13
Active
VS

IKT

Biological Products, (No Diagnostic Substances)
Inhibikase Therapeutics, Inc.
Quality
4.4
out of 10
Value Trap
24
SAFE
Price
$1.75
Last close
Models
9/13
Active

Model-by-Model Comparison

ModelType GNTA Fair ValueGNTA Upside IKT Fair ValueIKT Upside
Bayesian DCF Intrinsic $0.23 -77.6% $0.66 -62.4%
Earnings Power Value Intrinsic $0.34 -82.4%
EROIC Spread Intrinsic $•••.•• ••.•% $•••.•• ••.•%
First Chicago Scenario $•••.•• ••.•% $•••.•• ••.•%
ML-RIV Intrinsic $•••.•• ••.•% $•••.•• ••.•%
Dynamic NAV Asset-Based $0.80 -22.7% $1.03 -41.0%
PWERM Option-Based $•••.•• ••.•% $•••.•• ••.•%
Sentiment SOTP Hybrid $•••.•• ••.•% $•••.•• ••.•%
CUCE Ensemble Ensemble $•••.•• ••.•% $•••.•• ••.•%
🔒

Unlock Full 13-Model Comparison

Access all valuation models for GNTA vs IKT — including EROIC Spread, First Chicago, Markov DDM, PWERM, and 7 more.

Access Full Analysis — From $27/mo →

GNTA vs IKT — Which Stock Is More Undervalued?

GNTA scores higher with a 4.7/10 quality rating vs IKT's 4.4/10. Both stocks are analyzed daily using SEC EDGAR filings across 13 independent models.

Comparing Genenta Science S.p.A. (GNTA) and Inhibikase Therapeutics, Inc. (IKT) across 13 institutional-grade valuation models reveals how each company's intrinsic value stacks up against its market price. CirclFi's engine processes SEC EDGAR 10-K and 10-Q filings, FRED macroeconomic data, and GDELT news sentiment to generate independent fair value estimates daily.

GNTA currently trades at $1.03 with a QOC of 4.7/10, while IKT trades at $1.75 with a QOC of 4.4/10.

Both companies are analyzed with models spanning intrinsic (Bayesian DCF, EPV), scenario-based (First Chicago), regime-switching (Markov DDM, RCMH-DCF), machine learning (ML-RIV, FTNN Topology), and ensemble methods (CUCE).